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The development of resistance by the parasite against 
first line and second line antimalarial drugs, has under-
scored the importance to develop new drug targets 
and pharmacophores to treat the disease. The absence 
of a vaccine for protection and the availability of  
artemisinin and its derivatives as the only option has 
made the situation rather serious. With the availabil-
ity of increased support for malaria research, a vari-
ety of drug targets and candidate molecules are now 
available for further development. However, the suc-
cess rate of a candidate molecule to become a drug is 
very low and it does become necessary to start with a 
large basket, identified on a rational basis. This re-
view focuses on the present efforts to identify a variety 
of drug targets in the malaria parasite and to develop 
candidate drug molecules.  
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ALL intervention strategies do not seem to have con-
trolled malaria, which still takes its toll of 1–2 million 
deaths every year. An effective vaccine is not in sight and 
the parasite has developed resistance to frontline antimalar-
ials such as chloroquine and antifolates (sulfadoxine + 
pyrimethamine). Artemisinin and its derivatives (ART) 
seem to be the only effective antimalarials in the basket 
and the situation calls for major initiatives to discover 
new antimalarials. This review focuses on the efforts to 
discover and develop new antimalarials.  
Cell cycle as a drug target 
Cyclin-dependent kinases (CDKs) play an important role 
in cell cycle progression and are conserved in all euka-
ryotic species1. CDKs have been investigated as possible 
drug targets that include cancer, infectious diseases, car-
diovascular and neurological disoders2,3. CDK7 is an up-
stream kinase that activates other CDKs in the cell 
cycle4,5. Among the CDKs identified in Plasmodium fal-
ciparum, Pfmrk shares the highest homology with CDK7 
(ref. 6). Pfmrk associates with Pfcyc-1 and phosphory-
lates the carboxy terminal domain of RNA polymerase II, 
just as is the case with CDK7 (ref. 7). With the use of 
high throughput screening assays, chemical synthesis as 
well as virtual screening and computer-aided design, at-
tempts are underway to develop molecules that could act 
as universal Plasmodium CDK inhibitors. Based on the 
three-dimensional structure of pfmrk obtained through ho-
mology modelling, the similarities and differences with 
known CDKs have been studied. Starting with known 
CDK inhibitors, indorubin-3-monoxime was identified as 
a template compound and a starting point for iterative 
screening process. Most potent activity was obtained with 
quinolinone and oxindole compounds. Further iterative 
searching of chemical databases has identified chalcones 
and tryptanthrins as potent inhibitors with greater speci-
ficity for Pfmrk3. 
Metabolic pathways in the apicoplast as drug 
targets  
The identification of the 35 kb extrachromosomal DNA 
established the plastid origin of the apicoplast in P. falci-
parum and the apicomplexan parasites8. It is proposed that 
a secondary endosymbiotic event, where a red algal cell 
engulfed by an ancestral alveolate protist was acquired by 
the parasite, gave rise to the plastid organelle. The 35 kb 
apicoplast DNA codes for a full set of tRNAs, a few ribo-
somal proteins, three genes for the subunits of an oli-
gomeric RNA polymerase, a gene for the elongation 
factor PfTu and a gene contributing to the Fe–S pathway. 
The plastid organelle lost most of its other genes to the 
nucleus and is incapable of photosynthesis9.  
 The origin of apicoplast proteins has attracted a signi-
ficant investigation. There is consensus that the nuclear-
coded apicoplast proteins carry a bipartite signal at the N-
terminal end. After entering the secretory pathway, the 
signal peptide is cleaved of, exposing the transit peptide 
that has a specific recognition mechanism to transit the 
multimembrane structure of the apicoplast10,11. Although 
transit peptides do not have a unique primary or secon-
dary structure to carry out specific targeting, it is pro-
posed that a chaperone may impart a characteric structure 
with specificity12. It has been possible to develop an algo-
rithm to define a set of rules predicting the apicoplast- 
targeted protein13. A total of 551 proteins have been pre-
dicted to be targeted to the apicoplast14, although experi-
mental proof is perhaps available with only about 10–15% 
of the predicted Open Reading Frames (ORFs). These in-
clude: enzymes of fatty acid, isoprenoid and haem bio-
synthesis, subunits of DNA gyrase, Ti protease and 
ferredoxin. The predictions need not be absolute and each 
case has to be validated experimentally.  
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Fatty acid biosynthesis 
The genome of P. falciparum contains the genes for fatty 
acid synthase II (FAS II) pathway14. Earlier, individual 
studies had identified and located the FAS II enzymes in 
the apicoplast11,15. FAS I pathway involves multifunctional 
enzymes catalysing the elongation steps and is found in 
the cytosol of fungi and eukaryotes. In the FAS II path-
way, each reaction is catalysed by a discrete enzyme and 
is present in algae and plants16. Figure 1 depicts the fatty 
acid biosynthetic pathway. Malonyl-ACP is the starting 
point and is produced from malonyl CoA and ACP, cata-
lysed by the enzyme Malonyl CoA : ACP transacetylase 
(FabD). Malonyl-ACP condenses with acetyl-CoA to give 
β-ketoacyl ACP, catalysed by the enzyme β-ketoacyl-ACP 
synthase III (FabH). Three enzymes, namely β-ketoacyl-
ACP reductase (FabG), β-hydroxy acyl-ACP dehydratase 
(FabA or FabZ) and enoyl-ACP reductase (FabI) sequen-
tially convert β-ketoacyl-ACP to Acyl-ACP. This product  
will condense with another molecule of malonyl-ACP 
and produce β-ketoacyl-ACP. This reaction is catalysed 
 
 
 
Figure 1. Hypothetical pathways for the formation of fatty acids 
(FAS II) and isoprenoids (non-mevalonate) in the apicoplast. Different 
components of the pathway have been identified at various levels: gene 
annotation, bioinformatics tools, enzyme activity, etc. Abbreviations: 
DOXP, 1-deoxy-D-xylulose-5-phosphate; IspC(Dxr), 1-deoxy-D-
xylulose-5-phosphate reductase; IspD(Ygbp), 4-diphospho cytidyl-2C-
methylerythritol synthase; IspE (YchB), 4-diphosphocytidyl-2C-
methyl-D-erythritol kinase; IspF(YgbB), 2C-methyl-D-erythroitol 2,4 
cyclodiphosphate synthase; IspG(GcpE), (E)-4-hydroxy-3-methylbut-
2enyl diphosphate synthase; IspH(LytB), (E)-4-hydroxy-3-methylbut-2 
enyldiphosphate reductase.  
by β-ketoacyl–ACP synthase I (FabB) or β-ketoacyl-ACP 
synthase II (FabF) depending on chain length. This prod-
uct will go through a second cycle of reactions catalysed 
by FabG, FabZ (or FabA) and Fab I, extending the acyl-
ACP product by two carbons.  
 In the apicomplexan parasites including the Plasmo-
dium species, the enzymes of the fatty acid biosynthetic 
pathway are predicted to be localized in the apicoplast, 
based on the N-terminal extensions suggesting such a lo-
calization17. Malonyl-CoA itself is formed from acetyl-
CoA and biocarbonate and a single acetyl-CoA carboxylase 
(ACCase) is predicted to be localized to the apicoplast in 
the Plasmodium genome. Toxoplasma gondii has two 
ACCases, one in the cytosol and another in the api-
coplast. It has been shown that only the plastidic ACCase 
is sensitive to acryloxyphenoxy propionate herbicides18. 
The inhibitors act on the carboxyl-transferase (CT) domain 
of ACCase as revealed by the crystal structure of the CT 
domain of yeast ACCase with the inhibitors19. Although 
the growth of P. falciparum is inhibited by a fairly high 
concentration of the inhibitors (100–200 µM), these could 
be the starting molecules for further modifications, since 
they are non-toxic to mammalian cells. ACP is the other 
component needed to generate malonyl-ACP. PfACP en-
codes a protein product of 137 amino acids with a 60 
amino acid bipartite sequence at the N-terminus. The po-
tential of PfACP as a drug target needs to be explored20.  
 Among the enzymes of the FASII pathway in P. falci-
parum, FabI or enoyl-ACP reductase, catalysing the final 
step in the chain elongation cycle, has been investigated 
in great detail from the viewpoint of identifying potent 
inhibitors. The N-terminus of this gene product carries a 
bipartite sequence with potential to target the protein to 
the apicoplast. The enzyme catalyses the conversion of 
trans-2-acyl-ACP to acyl-ACP and requires NADH as the 
cofactor. Based on the potential of compounds to inhibit 
the bacterial enoyl-ACP reductase21, the inhibitory effects 
of triclosan, diazoborine, isoniazid and ethionamide on 
the Plasmodium enzyme and growth in culture have been 
studied. Triclosan has been shown to inhibit the growth 
of P. falciparum in culture with an IC50 value around 
1 µM22,23. It also inhibits radiolabelled acetate incorpora-
tion into fatty acids. The structural basis for the inhibition 
of the Pfenoyl-ACP reductase by triclosan has been investi-
gated based on the resolution of the crystal structure24 as 
well as kinetic studies using the recombinant enzyme25. It is 
inferred that triclosan traps the enzyme in the non-
productive NAD+ cofactor state, inhibiting the binding of 
NADH. The cofactor has a critical role in the binding of 
the inhibitors such as thienodiazaborine, imidazoles, 
aminopyridines and naphthyridinones26. Triclosan itself 
has not been found suitable for therapeutic use22 with a 
very high potential for resistance development by a single 
A217V mutation in the enzyme25. A 6-hydroxy naphtha-
lene derivative of triclosan with a Ki around 150 nM  
appears to have a potential for further development27.  
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 Major drug-screening efforts involving drug companies 
and academic institutions using triclosan and isonicotinic 
hydrazide as the starting molecules are underway. Syn-
thesis of additional compounds guided by structure-based 
molecular modelling and docking simulations are being 
employed. Two pyrazole compounds, Genz-8575 and 
Genz-10850, have been found to inhibit the drug-resistant 
and drug-sensitive enzyme at 32 µM and 18 µM, respec-
tively. These are from a library screened against the M. 
tuberculosis enzyme and are structurally different from 
triclosan. Another interesting development is the creation 
of transgenic P. berghei parasites with the Pfenoyl-ACP 
reductase replacing the endogenous counterpart to serve 
as an in vivo mice model for studying drug efficacy26.  
 Three condensing enzymes β-ketoacyl-ACP synthases 
(PfKAS I, II & III) essentially involved in chain initiation 
and FabB/F (I & II) involved in chain elongation are also 
being investigated as possible drug targets. P. falciparum 
appears to code for a single enzyme with 37% and 31% 
identity to the E. coli FabF and FabB, respectively and 
therefore the enzyme is designated as PfKAS I/II26. Thio-
lactomycin analogues such as 1,2-dithiole-3-one deriva-
tives are inhibitors of PfKAS III (FabH), having an IC50 
as low as 0.5 µM. Similarly cerulenin and its derivatives 
are also suggested for development as inhibitors for 
PfKAS I/II26. The availability of crystal structures of 
thiolactomycin, cerulenin and fatty acid bound bacterial 
KAS I/II enzymes can provide the basis for the develop-
ment of inhibitors for the parasite enzyme28.  
 Major drug discovery programmes have been initiated 
to screen for PfKAS III inhibitors from compound librar-
ies using a pharmacophore-guided in silico screen. The 
pharmacophore template is then used as a query to search 
chemical databases for new inhibitors and the potential 
hit compounds further screened for ADME properties. 
This effort has led to around 40 compounds with IC50 
values lower than 10 µM26.  
 β-ketoacyl–ACP reductase (PfKAR, FabG) catalyses 
the reduction of β-ketoacylACP to β-hydroxyacylACP in 
presence of NADPH and the latter is converted to trans-2-
acyl-ACP by the dehydratase enzyme (PfHAD, FabA/Z). 
PfKAR is considered as an ideal target, since it is found 
as a single isoenzyme. However, no specific inhibitor of 
PfKAR is known at present. The structure of PfHAD has 
been modelled using the E. coli enzyme as template and 
two compounds, NAS-21 and NAS-91, have been found 
to inhibit at around 1 µM. The IC50 values in culture were 
found29 to be 100 µM for NAS-21 and 7.4 µM for NAS-
91. Further, PfHAD has been crystallized30, providing a 
basis for structure-based inhibitor screening.  
Isoprenoid biosynthesis  
Isoprenoids, consisting of isopentenyl pyrophosphate (IPP) 
repeat units, form prosthetic groups of some enzymes and 
are also used in the synthesis of ubiquinone and dolichol. 
The malaria parasite genome provides evidence for the 
presence of the non-mevalonate pathway for IPP biosyn-
thesis (Figure 1). The presence of 1-deoxy-D-xylose-5-
phosphate (DOXP) synthase in the parasite genome was 
first reported by Jomaa et al.31. The pathway has been 
characterized in more detail recently9. The DOXP path-
way utilizes pyruvate and glyceraldehyde-3-phosphate to 
give DOXP, catalysed by the enzyme DOXP synthase. 
DOXP is also utilized for the biosynthesis of thiamine 
pyrophosphate and pyridoxal. Including an auxiliary pro-
tein, eight enzymes are required for the formation of 
isopentenyl pyrophosphate and dimethyl allylpyrophos-
phate (DMAPP) and the Plasmodium genome has homo-
logues for all the genes with potential for apicoplast 
targeting of the proteins32.  
 The mechanism of export of IPP and DMAPP is not 
clear, but the close association of the apicoplast with the 
mitochondrion is visualized to facilitate its import, facili-
tating ubiquinone biosynthesis in the mitochondrion. 
Similarly, IPP is also likely to be involved in the pre-
nylation of proteins in the parasite cytoplasm, where spe-
cific prenyl transferases have been identified9,38.  
 Fosmidomycin, an inhibitor of DOXP reducto-
isomerase, has antimalarial activity31. A clinical trial with 
fosmidomycin indicates that although the drug clears the 
parasite, it is prone to recrudescence34,35 and a useful syn-
ergy has been found between fosmidomycin and clinda-
mycin in preliminary studies36.  
Haem biosynthesis  
Studies in this laboratory had shown that the malarial 
parasite synthesizes haem de novo, despite accumulating 
haem derived from red cell haemoglobin as haemozoin 
pigment. Inhibition of the pathway with a specific inhibi-
tor such as succinylacetone leads to death of the para-
site37. While animals use glycine and succinyl-CoA to 
make δ-aminolevulinic acid (ALA), the committed pre-
cursor for haem biosynthesis, plants utilize glutamate to 
make ALA in a 3-step reaction38.  
 Studies in this laboratory had also shown that the para-
site (P. falciparum) imports host ALA dehydratase from 
the red cell39 and inhibition of this import process by the 
N- and C-terminal deleted fragment of host ALAD added 
to a culture of P. falciparum blocks this import, leading to 
inhibition of haem synthesis and death of the parasite40. 
More recent studies have shown that the parasite imports 
ferrochelatase, the terminal enzyme of the haem-bio-
synthetic pathway, from the host red cell and the parasite 
cytosol is capable of independent haem synthesis in vitro 
starting from ALA, suggesting the presence of all the 
down stream enzymes of the pathway of likely host origin41.  
 At the same time, the P. falciparum genome reveals the 
presence of all the genes of the haem-biosynthetic path-
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way with the exception of uroporphyrinogen III synthase 
that is yet to be annotated32. Studies in this laboratory have 
shown that the parasite genome-coded ALA synthase 
(PfALAS), catalysing the formation of ALA from glycine 
and succinyl-CoA, is localized to the parasite mitochon-
drion42. Based on the localization of the GFP reporter in 
promoter–reporter fusion gene transfected parasites, Sato 
et al.43 have also shown that PfALAS is localized to the 
parasite mitochondrion. In addition, they have also shown 
that PfALAD and PfPBGD (porphobilinogen deaminase) 
are targeted to the apicoplast. Studies in this laboratory 
have also shown by immunoelectron microscopy that the 
native PfALAD of the parasite is localized to the api-
coplast44. The terminal enzymes of the pathway, PfCPO, 
PfPPO and PfFC do not manifest an N-terminal sequence 
targeting to the apicoplast and, therefore, Sato et al.43 
have suggested that these could be targeted to the parasite 
cytosol or mitochondrion. They have further speculated 
that while, PfPPO and PfFC could be mitochondrial, 
PfCPO could be cytosolic in terms of localization. Stud-
ies in this laboratory have, however, shown that the na-
tive PfFC is localized to the apicoplast as analysed using 
immunoelectron microscopy41. These results have been 
contested on the basis that in PfFC–GFP fusion gene 
transfected parasites, the reporter is targeted to the mito-
chondrion45. It is not clear at this stage whether there 
could be two PfFC species in the parasite. The present in-
formation regarding the localization of the parasite ge-
nome-coded and host-derived enzymes of the haem 
biosynthetic pathway in P. falciparum is summarized in 
Table 1.  
 
 
 
Table 1.
 Localization of parasite genome-coded (Pf) and host-derived 
 (h) haem biosynthetic enzymes in P. falciparum 
Enzyme  Localization  
 
PfALAS Mitochondria 
PfALAD Apicoplast  
hALAD Cytosol 
PfPBGD Apicoplast 
hPBGD ?* 
 PfUROS Not annotated 
hUROS ?* 
PfUROD Apicoplast (?)** 
hUROD ?* 
PfCPO Cytoplasm (?)**, Mitochondria(?)** 
HCPO ?* 
PfPPO Mitochondria (?)** 
hPPO ?* 
PfFC Apicoplast/Mitochondria 
hFC Cytosolic 
*Unknown; **Experimental validation required. 
Abbreviations: ALAS, δ-aminolevulinate synthase; A; ALAD. δ-amino-
levulinate dehydratase; PBGD, porphobilinogen deaminase; UROS, 
uroporphyrin III synthase; UDOD uroporphyrinogen III decarboxylase; 
CPO, coproporphyrinogen III oxidase; PPO, protophorphyrinogen IX 
oxidase; FC, ferrochelatase.  
 A hybrid pathway for haem biosynthesis involving the 
parasite genome coded enzymes localized in the mito-
chondrion, apicoplast and cytosol with the eventual forma-
tion of haem in the mitochondrion has been proposed9,43,45. 
The results obtained in this laboratory, however, show 
that the parasite cytosol and the organellar fractions are 
capable of independent haem synthesis41. The imported 
host ALAD and FC in the parasite account for more than 
75–80% of the total respective enzyme activities in the 
parasite41,44. These results suggest the possibility that 
there could be two independent haem biosynthetic path-
ways in the parasite, one catalysed by the imported host 
enzymes and the other catalysed by the parasite genome-
coded counterparts.  
 Further studies are needed to establish the need for two 
independent pathways of haem biosynthesis in the para-
site. At the same time, experimental proof for the actual 
localization of native PfPBGD, PfUROD, PfCPO and 
PfPPO and their imported host counterparts needs to be 
obtained. Mechanisms for shuttling of the intermediates 
between compartments need to be understood to validate 
the proposed hybrid pathway. 
 Inhibition of the haem-biosynthetic pathway by suc-
cinyl acetone or the import of host-derived enzymes leads 
to death of the parasite37. Studies in this laboratory have 
shown that the biochemical properties of PfALAS42 and 
PfALAD44 are different from those of the corresponding 
host enzymes and that both components are needed for 
parasite survival. Therefore, the complex haem-
biosynthetic pathway of the malaria parasite would con-
stitute an ideal drug target. 
DNA transactions  
As already mentioned, the 35 kb apicoplast DNA has a 
marginal coding potential and undergoes replication, 
transcription and translation, essentially following a pro-
karyotic mechanism. A number of antibacterial compounds 
inhibiting this prokaryotic machinery act as slow acting 
antimalarials46. Tetracyclins, clindamycin, macrolids and 
chloramphenicol inhibit different steps in protein synthe-
sis. Quinolone inhibits DNA gyrase and rifampicin inhib-
its RNA polymerase. All these compounds have been 
shown to cause delayed death, manifesting the effects in 
the cycle succeeding that in which the additions have 
been made47.  
 At the level of protein synthesis, peptide deformylase 
from P. falciparum, that deformylates N-formylmethionine 
of the newly synthesized protein has been investigated as 
a possible drug target. The Plasmodium enzyme shows 
structural differences with that of the E. coli enzyme and 
many inhibitors (e.g. iron chelators) have been identified 
for further development48,49. Earlier studies from this 
laboratory had shown that chloroquine inhibits parasite 
protein synthesis by chelating haem and activating 
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eIF2α-kinase leading to enhanced phosphorylation of 
eIF-2α50 ¢.  
 Although the antibiotics mentioned are slow acting, 
combinations such as clindamycin and quinine51 and azi-
thromycin and artesunate52 are effective in clinical trials.  
Other apicoplast targets  
Fe–S clusters play an important role as prosthetic groups 
of enzymes and proteins involved in the electron transfer 
of redox and non-redox catalysed reactions and anabolic 
pathways. These clusters are found in mitochondria as 
well as chloroplasts in plants. An orthologue of sufB has 
been annotated in the plastid genome of P. falciparum53. 
Candidate genes for sufC, sufA, sufD, sufE and sufS have 
all been located in the P. falciparum database. Evidence 
has been obtained that sufC is targeted to the apicoplast 
and it would interact with sufB. SufS is a desulphurase 
generating sulphur to be incorporated into the Fe–S clus-
ter and it has been shown that in the presence of sufE, 
sufBCD complex can stimulate the desulphurase activity 
by 30-fold. SufD is implicated in iron mobilization9. In 
addition to the suf operon, two other operons, nif and isc, 
have been implicated in Fe–S cluster assembly54.  
 Fe–S cluster is also involved in the maturation of 
apoferredoxin and a Plasmodium orthologue of a NIF 
protein from A. thaliana, involved in the transfer of Fe–S 
cluster to apoferredoxin has been identified among the 
lypothetical proteins of the parasite. Fe–S clusters are 
also needed for the two terminal enzymes of the isopre-
noid pathway9, as well as lipoic acid synthase55. The ex-
tensive involvement of the suf system in the apicoplast in 
providing the reducing capacity and repairing oxidative 
damage to facilitate fatty acid and isoprenoid synthesis is 
visualized to make it an attractive drug target9.  
 Lipoic acid is an essential cofactor of pyruvate dehy-
drogenase and other dehydrogenases. Two isoforms of li-
poic acid synthase, LipA and LipB, are predicted to be 
plastidic in nature in P. falciparum55. A biosynthetic 
pathway involving lipoic acid synthase and lipoyl (oc-
tonoyl)–ACP : protein N6-lipoyl transferase B has been 
identified in the apicoplast, which is visualized to provide 
exogenous lipoic acid to the mitochondrial α-keto acid 
dehydrogenase complex involving lipoate protein ligaseA. 
These pathways are also considered as excellent drug tar-
gets56.  
Mitochondrial targets 
The P. falciparum mitochondrion is atypical. In the asex-
ual stage, it lacks the cristae, but perhaps, develops cris-
tae in the gametocyte stage57. The mitochondrion is 
closely associated with the apicoplast at all stages of 
parasite development. It has a small genome of 6 kb, en-
coding the genes for cytochrome b, cytochrome oxidase I 
and III, besides fragmented tRNA58,59. It acquires several 
nuclear gene-coded proteins through import mechanisms 
involving Tim–Tom complexes.  
 The organization and role of the parasite mitochondrion 
has been envisaged through a bioinformatics approach 
based on data mining from the P. falciparum genome, 
with experimental evidence being available in a limited 
number of cases45. An assessment of the main functions 
of a typical mitochondrion would indicate its roles in en-
ergy generation, electron transport and intermediary me-
tabolism. In all these cases, the role of the parasite 
mitochondrion remains unclear.  
 The Plasmodium derives its energy through glycolysis 
and there is no evidence that it leads to the formation of 
acetyl-CoA. The citric acid cycle itself appears dys-
functional, although the genes for most of the component 
enzymes can be identified in the database. The electron 
transport chain appears to function via the FAD-linked 
tricarboxylic acid cycle enzymes, malate-quinone oxi-
doreductase and succinate dehydrogenase. Coenzyme Q 
(uniquinone) occupies a pivotal position and at least five 
enzymes in P. falciparum can transfer electrons to this 
molecule. Clear cut evidence is available in the case of 
dihydroorotate dehydrogenase localized to the inner 
membrane of the mitochondrion. The dihydroorate syn-
thesized in the cytosol is converted to orotate in the mito-
chondrion by dihydroorotate dehydrogenase transferring 
the electrons to coenzyme Q45. Plasmodium does not 
have a salvage pathway for pyrimidine biosynthesis and 
de novo pyrimidine biosynthesis is an ideal drug target. 
Recently, it has been shown that the malarial parasite 
maintains an active electron transport chain just to serve 
one metabolic function, namely to regenerate ubiquinone 
required as the electron acceptor for dihydroorotate de-
hydrogenase60.  
 This leaves the role of FAD-linked tricarboxylic acid 
cycle enzymes, malate : quinone oxidoreductase and suc-
cinate dehydrogenase in electron transport to be clarified. 
The contribution of electrons donated from cytosolic and 
mitochondrial NADH and NAD(P)H to the electron 
transport chain also needs to be understood and in this 
context an understanding of the localization and function 
of NAD(P)H dehydrogenase and glycerol-3-phosphate 
dehydrogenase is important. The NAD(P)H dehydrogenase 
in P. falciparum does not have a human counterpart and, 
therefore, is a unique drug target45. A recent study has 
shown that the over expression of yeast NAD(P)H dehy-
drogenase enhances the sensitivity to artemisinin and ab-
lation lowers the sensitivity to the drug. Expression of the 
PfNAD(P)H dehydrogenase in such an yeast restored the 
sensitivity, attesting to the role of the parasite enzyme in 
mediating the effects of aretemisinin61.  
 Atovaquone was developed as an antimalarial, target-
ing against ubiquinol-cytochrome C oxidoreductase and 
collapsing the membrane potential as well. However, 
resistance to atavaquone developed very quickly and the 
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combination drug atovaquone–proguanil has been found 
to be effective, but expensive62. Orotidine decarboxylase 
catalysing the conversion of orotidine monophosphate to 
uridine monophosphate has also been investigated as a 
unique drug target and novel pyrimidine derivatives are 
also under investigation as potential antimalarials63.  
 The parasite mitochondrion has also possible roles to 
play in folate, Fe–S cluster and haem biosynthesis and 
with experimental validation many steps in these path-
ways could become drug targets. While apicoplast Fe–S 
clusters are involved in isoprenoid biosynthesis and other 
pathways mentioned earlier, the mitochondrion, perhaps, 
contributes to Fe–S complexes in the cytosol and some 
enzymes functioning in the mitochondrion. It is also of 
importance to assess the role of the parasite mitochon-
drion in stages other than that of the red cell stage. Re-
ports have indicated that the parasite mitochondrial 
functions are upregulated in the mosquito stage64,65. 
Cytosolic targets 
The folate pathway has been a major drug target with the 
combination of pyrimethamine, inhibiting dihydrofolate 
reductase (dhfr), and sulfadoxine, inhibiting dihydro-
pteroate synthase (dhps), proving to be an effective and 
cheap antimalarial combination. Unfortunately, resistance 
to this combination has become widespread66. A new com-
bination, lapdapTM, consisting of proguanil (a triazine meta-
bolite) inhibiting dhfr and dapsone inhibiting dhps has 
been found to be effective in Africa67, although its effi-
cacy in South East Asia, where the parasite has developed 
four mutations in the dhfr gene, is open to question. P-15, 
a biguanidine precursor of diaminotriazine derivative in 
combination with dhps inhibitors is being developed as a 
combination therapy against folate-resistant P. falcipa-
rum cases. There is also an effort to make methotrexate 
and aminopterin, potent inhibitors of dhfr, in situ from 
non-toxic precursors, in view of their toxicity to the 
host68.  
 Since Plasmodium derives most of its energy through 
glycolysis, inhibitors of this pathway have been investiga-
ted for antimalarial activity. One of the well-investigated 
targets is Pf lactate dehydrogenase (PfLDH). Structural 
information on the enzyme co-crystallized with inhibitors 
including oxamic acid and chloroquine is available. A 
large effort is focused on developing PfLDH inhibitors 
such as gossypol derivatives and naphthoic acid-based 
compounds69. Although a clinically relevant candidate 
molecule is not yet available, this target needs to be fur-
ther investigated. 
 Another glycolytic enzyme that has attracted attention 
is the triose phosphate isomerase (TPI). Structural differ-
ences between the human and PfTPI have been observed, 
including the mutation of a conserved mammalian serine 
residue near the active site to a phenylalanine in the para-
site enzyme. This can have profound effects on the inter-
play between the active site catalytic loop and inhibitors 
that could have therapeutic possibilities70.  
 Plasmodium does not manifest the de novo pathway for 
purine nucleotide biosynthesis and depends on the sal-
vage pathway for its supply of purines. Some of the en-
zymes of the salvage pathway have been investigated as 
potential drug targets. Purine nucleoside phosphorylase 
(PfPNP) converts inosine or 5-methylinosine to hypoxan-
thine. Immucillin H, a potent inhibitor of PNP, kills the 
parasite in culture, but would also inhibit the host red cell 
enzyme. 5-Methylthio-imucillin H has been developed as 
a potent and selective inhibitor of PfPNP based on the 
crystal structure of the inhibitor-bound enzyme71.  
 Hypoxanthine-guanine-xanthine phosphoribosyl trans-
ferase (PfHGXPRT) catalyses the transfer of a phos-
phoribosyl group to hypoxanthine, xanthine or guanine to 
give the corresponding nucleotide. The structure of the 
enzyme is very similar to that of the host enzyme, although 
only the parasite enzyme is capable of utilizing xanthine 
as substrate. NMR and kinetic studies have indicated pos-
sibilities for selectivity in drug design based on structural 
differences72,73. Adenylosuccinate synthetase (PfAdSS) 
catalyses the first committed step in the purine salvage 
pathway giving rise to adenosine monophosphate. The 
crystal structure of PfAdSS containing Hadacidin, an aspar-
tate analogue, is available74. Threonine 307 appears unique 
to the parasite enzyme forming a hydrogen bond with the 
inhibitor. Unlike purine biosynthesis, the malaria parasite 
synthesizes pyrimidines de novo. The drug targets in this 
pathway have been discussed in the earlier section.  
 Thiols play an important role in maintaining the redox 
state of the cell and the malarial parasite is very sensitive 
to an oxidative environment. Therefore, inhibition of 
thiol metabolism is a potential strategy to develop antima-
larials. Plasmodium has a single isoform of glutathione-s-
transferase (PfGST, m or p class) and its crystal structure 
is available75. An extended hydrophobic pocket in the en-
zyme is considered suitable for drug targeting. Haemin 
has a stronger inhibition on PfGST than on the placental 
p class enzyme. Inhibition of PfGST can potentiate the 
inhibitory effect of chloroquine. Glutathione reductase is 
also a potential drug target. There is substantial differ-
ence in the geometry and internal surface chemistry of 
the inter subunit cavity of the homodimer between the 
parasite and mammalian enzyme. Methylene blue, a phe-
nothiazine drug, which inhibits the P. falciparum enzyme 
more than the human enzyme binds to this cavity. Thio-
redoxin reductase and glutathione reductase may have a 
competing physiological function to reduce glutathione 
disulfide and the essentiality of either enzyme for parasite 
survival needs to be proven76.  
 The discovery of shikimate pathway in the malaria 
parasite has opened up a new drug target, although cho-
rismate synthase is the only enzyme identified conclusi-
vely77. Direct immunological evidence is now available 
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for the localization of this enzyme in the parasite cytosol78, 
although partitioning of the pathway between the parasite 
compartments is not ruled out. The herbicide glyphosate, a 
selective inhibitor of 5-enolpyruvylshikimate-3-phosphate 
synthase, and analogues of shikimate inhibit the growth 
of P. falciparum. Computational methods have been used 
to provide evidence for the identification of shikimate 
pathway enzymes that were not detected in the P. falcipa-
rum genome annotation79.  
Food vacuole targets  
A major function of the food vacuole is to degrade the 
host red cell haemoglobin sequestered through the cyto-
stome machinery and provide amino acids to the parasite. 
This is brought about by a variety of proteases and inhibi-
tion of this process is well investigated as a drug tar-
get80,81. Massive degradation of haemoglobin also leads 
to generation of a large quantity of haem that is toxic to 
the parasite, promoting membrane damage due to its per-
oxidative properties. The most important pathway of 
haem detoxication in P. falciparum is the formation of 
haemozoin pigment. Detailed studies have revealed that 
haemozoin is a crystalline polymer and identical to β-
haematin with the haem units linked to each other 
through a coordinate bond between ferric iron of one unit 
and the propionate carboxyl group of the adjacent unit, 
the different cyclic dimers being linked through hydrogen 
bonds between the remaining carboxylate groups82. 
 The mechanism of haemozoin formation is a matter of 
debate. While it is essentially considered to be a non-
enzymatic process, various factors such as parasite lipids, 
hrpII protein, etc., have been shown to promote its forma-
tion. There are strategies to form haemozoin in vitro, 
providing a high throughput screening method for identi-
fying inhibitory molecules83. Chloroquine and many qui-
nolines have been shown to interact with haem, chloro-
quine non-covalently interacting with the growing face of 
the haemozoin crystal preventing further growth84. Blood 
schizonticidal antimalarials (e.g. quinine, quinidine, halo-
fantrine, mefloquine and 8-aminoquiniolines including 
tafequine as well as bisquinoline analogues) in general 
are visualized to act through this mechanism. Although the 
sequiterpene endoperoxide artemisinin was also shown to 
interfere with haemozoin formation, its action through the 
process of alkylation of proteins by the reactive interme-
diates generated through iron/haem-mediated activation 
of the endoperoxide bridge, has also been implicated85. 
Specific inactivation of PfATP6, a calcium ATPase, has 
been projected as the main target86. Many other com-
pounds such as hydroxamates, clotrimazole, pentamidine, 
cyprohepatidine, a variety of metalloporphyrins, natural 
compounds such as ellagic acid from the bark of Tris-
taniopsis calobuxus and terpene isonitriles from marine 
sponges have all been implicated to act as antimalarials 
through inhibiting haemozoin formation83. High through-
put screening of molecules to inhibit β-haematin forma-
tion in vitro has led to the identification of new candidate 
antimalarials such as triacylcarbinol and the related ben-
zophenone87.  
 As already mentioned, parasite proteases involved in 
haemoglobin degradation have been investigated as po-
tential drug targets. Detailed studies have shown that 
plasmepsins I and II (along with IV) are aspartic pro-
teases that initiate the degradative process. This is fol-
lowed by falcipains (I, II & III) that are cysteine 
proteases and the metalloprotease falcilysin88. At least ten 
plasmepsin genes have been identified and therefore, 
identifying a universal inhibitor may be a challenging 
task. While these events occur in the food vacuole, the pep-
tides have to be translocated to the cytoplasm, where spe-
cific aminopeptidases will cleave them to amino acids. 
Many groups of inhibitors for plasmepsins such as statins 
and hydroethylamines and for falcipains such as semicar-
bazones, vinylsulfones and isoquinolines have been in-
vestigated for antimalarial activity89. 
 A library of 1,4-bis(3-aminopropyl)piperazine has been 
investigated for inhibition of PfA-M1, a zinc amino-
peptidase in the parasite. This also has a quinoline struc-
tural component that can inhibit β-haematin formation. 
Hydroxamate derivatives have metalloprotease inhibitor ac-
tivity. It appears that a variety of derivatives can be de-
signed to inhibit the peptidase activity as well as β-
haematin formation90. Members of the methionine amino-
peptidase family have been examined as potential antima-
larial targets. From a library of 175,000 compounds, 
using one of the four cloned methionine peptidase 1a as 
target, a potent inhibitor containing a 2-(2-pyridinyl)-
pyrimidine core has been identified. The compound is ac-
tive against chloroquine-sensitive and chloroquine-resis-
tant strains of P. falciparum in culture as well as in vivo 
in the mouse model91.  
Membrane targets – Biosynthesis and transport 
During the intraerythrocytic stage, P. falciparum synthe-
sizes considerable amounts of membrane components in-
volving phospholipid metabolism92. An approach to inhibit 
de novo phosphatidyl choline biogenesis through the use 
of mono- and bis-quaternary ammonium salts mimicking 
choline structure has been evolved. These compounds were 
shown to inhibit choline entry into the infected erythro-
cytes and maximal activity was demonstrated with the de-
rivative E13 (N,N,N-tripropyl dodecan-1-ammonium 
bromide, IC50 of 33 nM)106. The bis-quaternary ammo-
nium compound G25 [1,6-hexamethylene-bis-(N-methyl-
pyrrolidinium) bromide] was significantly more active 
with an IC50 of 0.64 nM93.  
 Although the bis-quaternary ammonium salts are potent 
in parenteral administration, their bioavailability through 
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oral delivery is low. Therefore, bioisosteric analogues (bis-
amidimes) were tested, but without much success. This 
led to the synthesis of bis-thiazolium salts with appro-
priate substituents as prodrugs. The prodrug TE3, while 
having an IC50 in the range 1–2 nM was found to have an 
ED50 of 5 mg/kg with an absolute bioavailability of 
around 16% in Sprague-Dawley rats and a good therapeu-
tic index. These compounds have a dual mode of action 
on the intracellular parasite, inhibiting phosphotidyl cho-
line biosynthesis as well as forming complexes with pro-
toporphyrin IX to inhibit haemozoin formation in the 
cell-free system. These compounds are indicated to be 
more active than chloroquine/artemisinins and most po-
tent in the rodent model94. 
 New permeability pathways (NPPs) in the intra-
erythrocytic stage to supply nutrients to the parasite 
across the red cell membrane are also under investigation 
as drug targets. The NPPs are visualized to function to 
enhance supply of nutrients such as glucose, panto-
thenate, Na+, etc. or to deliver drugs as well as to efflux 
excess metabolites, such as lactic acid or amino acids95. 
Techniques based on radiotracer uptake, haemolysis, fluo-
rescence and electrophysiological methods have been 
used to screen compounds inhibiting the NPPs, which are 
essentially anion-selective96. The most potent blockers of 
NPP activity are based on furosemide and 5-nitro-2-(3-
phenylpropylamino) benzoic acid (NPPB) and the most 
effective derivatives have an IC50 around 100 nM97. The 
main issues are a lack of correlation between the inhibi-
tory activity on NPP and parasite growth and non-
selectivity due to inhibition of the RBC pathway compo-
nent.  
 Another important strategy is to use the NPP for selective 
targeting of antimalarials98, including the bis-quaternary 
ammonium compounds mentioned earlier. NPPs can also 
be used to deliver monovalent cationic moieties and non-
physiological stero-isomers such as the toxic-L-nucleosides 
that are not accessible to normal biological membranes95. 
Natural compounds as antimalarials  
Manzamine A, α-β-carboline alkaloid present in several 
marine sponges provides 90% clearance of P. berghei in 
mice after a single intraperitoneal injection and 40% of the 
mice survive after 40 days99. Cyclosporin A, an antifungal 
immunosuppressive agent and clotrimazole, another anti-
fungal compound, have all been found to have antimalarial 
properties. Recently, studies in this laboratory have shown 
that curcumin from turmeric has antimalarial activity100 
and a combination of α-β-arteether–curcumin therapy is 
able to completely prevent recrudescence due to arteether 
monotherapy and provide 100% protection against mor-
tality in P. berghei-infected mice101. In the context of ar-
temisinin-based combination therapies being looked upon 
as the strategy to prevent development of resistance and 
recrudescence, the curcumin–artemisinin derivative com-
bination therapy appears superior to many other combina-
tions being tested or used.  
 A study of plant species in rain forests of Madagascar 
for possible antimalarial compounds has led to the isola-
tion of a novel morphine compound named tazopsine 
from Strychnopsis thouarsii having a specific inhibitory 
action against the liver stage but not the blood stage para-
site. A simple modification of tazopsine to give N-
cyclopentenyl-tazopsine has improved the toxicity pro-
file, providing an alternative to primaquine, the only li-
censed drug available against hepatic stage malaria102. A 
variety of herbal medicine and traditional practices to 
treat malaria in different countries and societies is avail-
able and some have undergone clinical trials as well. But, 
an internationally acceptable, safe and efficacious regi-
men is yet to emerge, although there are many more 
herbal treatments used throughout the world than the 
validated antimalarial drugs103. The natural compound ar-
temisinin from the Chinese herb continues to inspire the 
synthesis of newer antimalarials. Vennerstrom et al.104 
utilized the endoperoxide bridge as the war head and syn-
thesized synthetic trioxalane derivatives with high oral 
bioavailability and optimal half-life, performing superior 
to the native compound. The derivative OZ277 is under 
clinical trial. More recently, Posner et al.105 have synthe-
sized new generation trioxane dimers from artemisinin 
and four of these cure malaria in infected mice with a 
single subcutaneous injection. 
Concluding remarks 
A difficult situation to treat malaria has arisen in view of 
the development of resistance of the parasite to front line  
 
Table 2. Summary of drug targets and candidate molecules against  
 the malaria parasite (typical examples) 
 Enzyme/ 
Target receptor Candidate molecule 
 
Cell Cycle MRK Quinolinones, oxindoles 
Apcicoplast Fab I  Triclosan derivatives, pyrazoles 
Apcicoplast Accase  Acryloxy phenoxy propionate 
Apcicoplast Fab A/Z NAS-21, NAS-91 
Apcicoplast Fab H  Thiolactomycin analogues 
Apcicoplast DOXR Fosidomycin 
Cytoplasm LDH Gossypol -, naphthoic acid 
   derivatives 
Apcicoplast PNP 5-Methylthio-iimucilin H 
Apcicoplast EPPS Shikimate derivatives  
Food vacuole  Haemozoin Triacyl carbinol and several  
   other compounds 
Food vacuole Proteases,  1,4-Bis(3-amino propyl) piperazine 
 Peptidases derivatives 
Membrane Phospholipid. …  Bis quaternary ammonium  
  Haemozoin  and Bbisthiazolium salts 
Natural ? Curcumin, Tazopsine derivatives 
compounds 
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antimalarials and the unavailability of a vaccine. At pre-
sent the main drug available in the basket is artemisinin 
(ART) and its derivatives and serious efforts are under-
way to develop ART-based combination therapies to extend 
the life of the drug. Therefore, all the targets and mole-
cules discussed in this review and elsewhere are impor-
tant with the realization that only a few would eventually 
make the grade. Typical examples of potential drug targets 
and candidate antimalarials are given in Table 2. In par-
ticular, new pharmacophores attacking different targets in 
the parasite can bring in new strategies to combat ma-
laria. Apart from efficacy, toxic side effects, pharmaco-
kinetic compatibility and potential to develop resistance 
would all be the major parameters in the eventual devel-
opment of a successful drug. Affected children and preg-
nant women would pose additional challenges. Above all, 
malaria is a poor man’s disease and therapies to be devel-
oped have to be affordable to the poor communities of the 
world that form the prime targets for the disease.  
 
 
 
1. Morgan, D. O., Cyclin-dependent kinases: Engines, clocks and 
microprocessors. Annu. Rev. Cell Dev. Biol., 1997, 13, 261–291. 
2. Waters, N. C. and Geyer, J. A., Cyclin-dependent protein kinases 
as therapeutic drug targets for antimalarial drug development. Ex-
pert Opin. Ther. Targets, 2003, 7, 7–17. 
3. Keenan, S. M., Geyer, J. A., Welsh, W. J., Prigge, S. T. and Wa-
ters, N. C., Rational inhibitor design and iterative screening in the 
identification of selective plasmodial cyclin dependent kinase in-
hibitors. Combinatorial Chem. High Throughput Screening, 2005, 
8, 27–38. 
4. Shuttleworth, J., The regulation and functions of cdk7. Prog. Cell 
Cycle Res., 1995, 1, 229–240. 
5. Kaldis, P. and Solomon, M. J., Analysis of CAK activities from 
human cells. Eur. J. Biochem., 2000, 267, 4213–4221. 
6. Li, J. L., Robson, K. J., Chen, J. L., Targett, G. A. and Baker, D. 
A., Pfmrk, a MO I5-related protein kinase from Plasmodium fal-
ciparum. Gene cloning, sequence, stage-specific expression and 
chromosome localization. Eur. J. Biochem., 1996, 241, 805–813. 
(erratum Eur. J. Biochem., 1997, 243, 537).  
7. Waters, N. C., Woodward, C. L. and Prigge, S. T., Cyclin H acti-
vation and drug susceptibility of the Pfmrk cyclin-dependent pro-
tein kinase from Plasmodium falciparum. Mol. Biochem. 
Parasitol., 2000, 107, 45–55. 
8. Wilson, R. J. M. et al., Complete gene map of the plastid-like 
DNA of the malaria parasite Plasmodium falciparum. J. Mol. 
Biol., 1996, 261, 155–172.  
9. Wilson, R. J. M., Parasite plastids: approaching the end game. 
Biol. Rev., 2005, 80, 129–153.  
10. Waller, R. F. et al., Nuclear-encoded proteins target to the plastid 
in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl. 
Acad. Sci. USA, 1998, 95, 12352–12357. 
11. Waller, R. F. et al., Protein trafficking to the plastid of Plasmo-
dium falciparum
 is via the secretory pathway. EMBO J., 2000, 19, 
1794–1802. 
12. Bruce, B. D., Chloroplast transit peptides: structure, function and 
evolution. Trends Cell Biol., 2000, 10, 440–447. 
13. Foth, B. J. et al., Dissecting apicoplast targeting in the malaria 
parasite Plasmodium falciparum. Science, 2003, 299, 705– 
708.  
14. Gardner, M. J. et al., Genome sequence of the human malaria 
parasite Plasmodium falciparum. Nature, 2002, 419, 498–511. 
15. Gardner, M. J. et al., Chromosome 2 sequence of the human ma-
laria parasite Plasmodium falciparum. Science, 1998, 282, 1126–
1132. 
16. Harwood, J. L., Recent advances in the biosynthesis of plant fatty 
acids. Biochem. Biophys. Acta, 1996, 1301, 7–56. 
17. Foth, B. J. and McFadden, G. I., The apicoplast: A plastid in 
Plasmodium falciparum and other apicomplexan parasites. Int. 
Rev. Cytol., 2003, 224, 57–110. 
18. Jelenksa, J., Crawford, M. J., Harb, O. S., Zuther, E., Haselkorn, 
R., Roos, D. S. and Gornicki, P., Subcellular localization of ace-
tyl-CoA carboxylase in the apicomplexan parasite Toxoplasma 
gondii. Proc. Natl. Acad. Sci. USA, 2001, 98, 2723–2728. 
19. Zhang, H., Tweel, B. and Tong, L., Molecular basis for the inhibi-
tion of the carboxyltransferase domain of acetyl-coenzyme A car-
boxylase by haloxyfop and diclofop. Proc. Natl. Acad. Sci. USA, 
2004, 101, 5910–5915. 
20. Waters, N. C. et al., Functional characterization of the acyl carrier 
protein (PfACP) and beta-ketoacyl ACP synthase III (PfKAS III) 
from Plasmodium falciparum. Mol. Biochem. Parasitol., 2002, 
123, 85–94. 
21. Campbell, J. W. and Cronan Jr., J. E., Bacterial fatty acid biosyn-
thesis: targets for antibacterial drug discovery. Annu. Rev. Micro-
biol., 2001, 55, 305–332. 
22. McCleod, R. et al., Triclosan inhibits the growth of Plasmodium 
falciparum
 and Toxoplasma gondii by inhibition of apicomplexan 
FabI. Int. J. Parasitol., 2001, 31, 109–113. 
23. Surolia, N. and Surolia, A., Triclosan offers protection against 
blood stages of malaria by inhibiting enoyl-ACP reductase of 
Plasmodium falciparum. Nature Med., 2001, 7, 167–173. 
24. Muench, S. P., Rafferty, J. B., McCleod, R., Rice, D. W. and 
Prigge, S. T., Expression, purification and crystallization of the 
Plasmodium falciparum
 enoyl reductase. Acta Crystallogr., 2003, 
D59, 1246–1248. 
25. Kapoor, M., Reddy, C. C., Krishnasastry, M. V., Surolia N. and 
Surolia, A., Slow-tight-binding inhibition of enoyl-acyl carrier 
protein reductase from Plasmodium falciparum by triclosan. Bio-
chem. J., 2004, 381, 719–724.  
26. Lu, J. Z., Lee, P. J., Waters, N. C. and Prigge, S. T., Fatty acid 
synthesis as a target for antimalarial drug discovery. Combinato-
rial Chem. High Throughput Screening, 2005, 8, 15–26. 
27. Perozzo, R. et al., Structural elucidation of the specificity of the 
antibacterial agent triclosan for malarial enoyl acyl carrier protein 
reductase. J. Biol. Chem., 2002, 277, 13106–13114. 
28. Price, A. C., Choi, K.-H., Heath, R. J., Li, Z., White, S. W. and 
Rock, C. O., Inhibition of β-ketoacyl-acyl carrier protein syn-
thases by thiolactomycin and cerulenin. Structure and mechanism. 
J. Biol. Chem., 2001, 276, 6551–6559.  
29. Sharma, S. K. et al., Identification, characterization and inhibition 
of Plasmodium falciparum β-hydroxy-acyl carrier protein dehy-
dratase (Fab Z). J. Biol. Chem., 2003, 278, 45661–45671. 
30. Swarna Mukhi, P. L., Sharma, S. K., Kapoor, M., Surolia, N., Su-
rolia, A. and Suguna, K., Crystallization and preliminary crystal-
lographic analysis of β-hydroxy acyl ACP dehydratase (Fab Z) 
from Plasmodium falciparum. Acta Crystallogr., Section D – 
Biol. Crystallogr., 2004, 60, 120–121. 
31. Jomaa, H. et al., Inhibitors of the non-mevalonate pathway of 
isoprenoid biosynthesis as antimalarial drugs. Science, 1999, 285, 
1573–1576. 
32. Ralph, S. A. et al., Metabolic maps and functions of the Plasmo-
dium falciparum
 apicoplast. Nature Rev. Microbiol., 2004, 2, 
203–216. 
33. Chakrabarti, D., Da Silva, T., Barger, J., Paquette, S., Patel, H., 
Patterson, S. and Allen, C. M., Protein farnesyltransferase and 
protein prenylation in Plasmodium falciparum. J. Biol. Chem., 
2002, 277, 42066–42073. 
34. Missinoll, A. M. et al., Fosidomycin for malaria. Lancet, 2002, 
360, 1941–1942. 
SPECIAL SECTION: MALARIA 
 
CURRENT SCIENCE, VOL. 92, NO. 11, 10 JUNE 2007 1554 
35. Lell, B. et al., Fosidomycin, a novel chemotherapeutic agent for 
malaria. Antimicrob. Agents Chemother., 2003, 47, 735–738. 
36. Wiesner, J., Henschker, D., Hutchinson, D. B., Beck, E. and 
Jomaa, H., In vitro and in vivo synergy of fosidomycin a novel 
antimalarial drug, with clindamycin. Antimicrob. Agents Chemo-
ther.
 2002, 46, 2889–2894. 
37. Surolia, N. and Padmanaban, G., De novo biosynthesis of heme 
offers a new chemotherapeutic target in the human malarial para-
site. Biochem. Biophys. Res. Commun., 1992, 187, 744–750. 
38. Grimm, B., Novel insights in the control of tetrapyrrole metabo-
lism of higher plants. Curr. Opin. Plant Biol., 1998, 1, 245– 
250. 
39. Bonday, Z. Q., Taketani, S., Gupta, P. D. and Padmanaban, G., 
Heme biosynthesis by the malarial parasite. J. Biol. Chem., 1997, 
272, 21839–21846. 
40. Bonday, Z. Q., Dhanasekaran, S., Rangarajan, P. N. and Padma-
naban, G., Import of host δ-aminolevulinate dehydratase into the 
malarial parasite: Identification of a new drug target. Nature 
Med., 2000, 6, 898–903. 
41. Varadharajan, S., Sagar, B. K. C., Rangarajan, P. N. and Padma-
naban, G., Localization of ferrochelatase in Plasmodium falcipa-
rum. Biochem. J., 2004, 384, 429–436. 
42. Varadharajan, S., Dhanasekaran, S., Bonday, Z. Q., Rangarajan, 
P. N. and Padmanaban, G., Involvement of δ-aminolevulinate 
synthase encoded by the parasite gene in de novo haem synthesis 
by Plasmodium falciparum. Biochem. J., 2002, 367, 321–327. 
43. Sato, S., Clough, B., Coates, L. and Wilson, R. J. M., Enzymes 
for heme biosynthesis are found in both the mitochondrion and 
plastid of the malaria parasite Plasmodium falciparum. Protist, 
2004, 155, 117–125. 
44. Dhanasekaran, S., Chandra, N. R., Sagar, B. K. C., Rangarajan, P. 
N. and Padmanaban, G., δ-Aminolevulinic acid dehydratase from 
Plasmodium falciparum
 – indigenous vs imported. J. Biol. Chem., 
2004, 279, 6934–6942. 
45. Van Dooren, G. G., Stimmler, L. M. and McFadden, G. I., Meta-
bolic maps and functions of the Plasmodium mitochondrion. 
FEMS Microbiol. Rev., 2006, 30, 596–630. 
46. Clough, B. and Wilson, R. J. M., Antibiotics and the plasmodial 
plastid organelle. In Antimalarial Chemotherapy: Mechanisms of 
Action, Resistance and New Directions in Drug Discovery (ed. 
Rosenthal, P. J.), Humana Press, Totawa, 2001, pp. 265–286. 
47. Fichera, M. E. and Roos, D. S., A plastid organelle as a drug tar-
get in apicomplexan parasite. Nature, 1997, 390, 407–409. 
48. Wei, Y., Yi, T., Huntington, K. M., Chaudbuty, C. and Pei, D., 
Identification of a potent peptide deformylase inhibitor from a ra-
tionally designed combinatorial library. J. Combinatorial Chem., 
2000, 2, 650–657. 
49. Hackbarth, C. J. et al., N-Alkyl urea hydroxamic acids as a new 
class of peptide deformylase inhibitors with antibacterial activity. 
Antimicrob. Agents Chemother., 2002, 46, 2752–2764. 
50. Surolia, N. and Padmanaban, G., Chloroquine inhibits heme-
dependent protein synthesis in Plasmodium falciparum. Proc. 
Natl. Acad. Sci. USA, 1991, 88, 4786–4790. 
51. Lell, B. and Kremsner, P. G., Clindamycin as an antimalrial drug; 
review of clinical trials. Antimicrob. Agents Chemother., 2002, 
46, 2315–2320. 
52. Ohrt, C., Willingmyre, G. D., Lee, P. J., Knirsch, C. and Milhous, 
W. K., Assessment of drugs against Plasmodium falciparum in vi-
tro. Antimicrob. Agents Chemother., 2002, 46, 2518–2524. 
53. Ellis, K. E. S., Clough, B., Saldhana, J. W. and Wilson, R. J. M., 
Nifs and Sufs in malaria. Mol. Microbiol., 2001, 41, 973–981. 
54. Tokumoto, U. et al., Network of protein–protein interactions 
among iron-sulfur cluster assembly proteins in Escherichia coli. 
J. Biochem., 2002, 131, 713–719. 
55. Thomsen-Zieger, N., Shachtner, J. and Seeber, F., Apicomplexan 
parasites contain a single lipoic acid synthase located in the plas-
tid. FEBS Lett., 2003, 547, 80–86.  
56. Gunther, S., McMillan, P. J., Wallace, L. J. M. and Muller, S., 
Plasmodium falciparum
 possesses organelle-specific α-kekto acid 
dehydrogenase complexes and lipoylation pathways. Biochem. 
Soc. Trans., 2005, 33, 977–980. 
57. Krungkrai, J., Prapunwattana, P. and Krungkrai, S. R., Ultrastruc-
ture and function of mitochondria in gametocytic stage of Plas-
modium falciparum. Parasite, 2000, 7, 19–26. 
58. Aldritt, S. M., Joseph, J. T. and Wirth, D. F., Sequence identifica-
tion of cytochrome b in Plasmodium gallinaceum. Mol. Cell Biol., 
1989, 9, 3614–3620. 
59. Feagin, J. E., Mericle, B. L., Werner, E. and Morris, M., Identifi-
cation of additional rRNA fragments encoded by the Plasmodium 
falciparum
 6 kb element. Nucleic Acids Res., 1997, 25, 438–446. 
60. Painter, H. J., Morrisey, J. M., Mather, M. W. and Vaidya, A. B., 
Specific role of mitochondrial electron transport in blood stage 
Plasmodium falciparum. Nature, 2007, 446, 88–91. 
61. Li, W. et al., Yeast model uncovers dual roles of mitochondria in 
the action of artemisinin. PLOS Genet., 2005, 1, e36. 
62. Vaidya, A. B., Atavaquone–proguanil combination. In Antimalar-
ial Chemotherapy: Mechanisms of Action, Resistance and New 
Directions in Drug Discovery
 (ed. Rosenthal, P. J.), Totawa, Hu-
mana Press, 2001, pp. 203–218.  
63. Fujihashi, M. et al., An unprecedental twist to ODCase catalytic 
activity. J. Am. Chem. Soc., 2005, 127, 15048–15050. 
64. Hall, Nl. et al., A comprehensive survey of the Plasmodium life 
cycle of genomic, transcriptomic and proteomic analyses. Sci-
ence, 2005, 307, 82–86. 
65. Khan, S. M. et al., Proteomic analysis of separated male and fe-
male gametocytes reveals novel sex-specific Plasmodium biology. 
Cell, 2005, 121, 675–687. 
66. Plowe, C. V., Folate antagonist and mechanisms of resistance. In 
Antimalarial Chemotherapy: Mechanism of Action, Resistance 
and New Directions in Drug Discovery
 (ed. Rosenthal, P. J.), 
Humana Press, Totowa, 2001,  pp. 173–190. 
67. Mutabingwa, T., Nzila, A., Mberu, E., Nduati, E., Winstanley, P., 
Hills, E. and Watkins, W., Chloroproguanil for treatment of drug-
resistant falciparum malaria in Tanzania. Lancet, 2001, 358, 
1218–1223. 
68. Biagini, G. A., O’Neill, P. M., Nzila, A., Ward, S. A. and Bray, P. 
G., Young guns or back to the future. Trends Parasitol., 2003, 19, 
479–487. 
69. Brady, R. L. and Cameron, A., Structure-based approaches to the 
development of antimalarials. Curr. Drug Targets, 2004, 5, 137–
149.  
70. Parthasarathy, S., Ravindra, G., Balaram, H., Balaram, P. and 
Murthy, M. R. N., Structure of the Plasmodium falciparum trio-
sephosphate isomerase–phosphoglycolate complex in two crystal 
forms. Characterization of catalytic loop open and closed confor-
mations of the ligand-bound state. Biochemistry, 2002, 41, 
13178–13188. 
71. Shi, W. et al., Plasmodium falciparum purine nucleoside phos-
phorylase: crystal structures, immucillin inhibitors and dual cata-
lytic function. J. Biol. Chem., 2004, 279, 18103–18106. 
72. Li, C. et al., Transition state analogs as inhibitors of human and 
malarial hypoxanthine-guanine phosphoribosyltransferases. Nature 
Struct. Biol., 1999, 6, 582–587. 
73. Subbayya, I. N. S. and Balaram, H., Evidence for multiple active 
states of Plasmodium falciparum hypoxanthine-guanine-xanthine 
phosphoribosyl transferase. Biochem. Biophys. Res. Commun., 
2000, 279, 433–437.  
74. Eaazhisai, K., Jayalakshmi, R., Gayathri, P., Anand, R. P., Suma-
thy, K., Balaram, H. and Murthy, M. R. N., Crystal structure of 
fully ligated adenylosuccinate synthetase from Plasmodium falci-
parum. J. Mol. Biol., 2004, 335, 1251–1264. 
75. Fritz-wolf, K. et al., X-ray structure of glutathione-S-transferase 
from the malarial parasite Plasmodium falciparum. Proc. Natl. 
Acad. Sci. USA, 2003, 100, 13821–13826. 
SPECIAL SECTION: MALARIA 
 
CURRENT SCIENCE, VOL. 92, NO. 11, 10 JUNE 2007 1555 
76. Muller, S., Liebau, E., Walter, R. D. and Krauth-Siegel, Thiol 
based redox metabolism of protozoan parasites. Trends Parasi-
tol., 2003, 19, 320–328. 
77. Roberts, F. et al., Evidence for the shikimate pathway in apicom-
plexan parasites. Nature, 1998, 393, 801–805. 
78. Fitzpatrick, T., Rickew, S., Lanzer, M., Amrhein, N., Macheroux, 
P.and Kappes, B., Subcellular localization and characterization of 
chorismate synthase in the apicomplexan Plasmodium falciparum. 
Mol. Microbiol., 2001, 40, 65–75. 
79. McConkey, G. A., Pinney, J. W., Westhead, D. R., Plueckhahn, 
K., Fitzpatrick, T. B., Macheroux, P. and Kappes, B., Annotating 
the Plasmodium genome and the shikimate pathway. Trends 
Parasitol., 2004, 20, 60–65. 
80. Banerjee, R., Liu, J., Beatty, W., Pelosof, L., Klemba, M. and 
Goldberg, D. E., Four plasmepsins are active in Plasmodium fal-
ciparum
 including a protease with an active site histidine. Proc. 
Natl. Acad. Sci. USA, 2002, 99, 990–995. 
81. Sijwalai, P. S. and Rosenthal, P. J., Gene disruption confirms a 
critical role for the cysteine protease falcipain-2 in hemoglobin 
hydrolysis by Plasmodium falciparum. Proc. Natl. Acad. Sci. 
USA, 2004, 101, 4384–4389. 
82. Pagola, S., Stephens, P. W., Bhole, D. S., Kosar, A. D. and 
Madsen, S. K., The structure of malaria pigment β-haematin. Na-
ture, 2000, 404, 307–310. 
83. Tekwani, B. L. and Walker, L. A., Targeting for hemozoin syn-
thesis pathway for new antimalarial drug discovery: Technologies 
for in vitro β-hematin formation assay. Combinatorial Chem. 
High Throughput Screening, 2005, 8, 63–79. 
84. Buller, R., Peterson, M. L., Almarsson, O. and Leiserowitz, L., 
Quinoline binding site on malarial pigment crystal: A rational 
pathway for antimalarial design. Crystal Growth Design, 2002, 2, 
553–562. 
85. Pandey, A. V., Tekwani, B. L., Singh, R. L. and Chauhan, V. S., 
Artemisinin, an endoperoxide antimalarial disrupts the hemoglo-
bin catabolism and heme detoxification systems in malarial para-
site. J. Biol. Chem., 1999, 274, 19383–19388. 
86. Eckstein-Ludwig, U. et al., Artemisinins target the SERCA of 
Plasmodium falciparum. Nature, 2003, 424, 957–960. 
87. Kurosawa, Y. et al., Hematin polymerization assay as a high 
throughput screen for identification of new antimalarial pharma-
cophores. Antimicrob. Agents Chemother., 2000, 44, 2638– 
2644. 
88. Eggleson, K. K., Duffin, K. L. and Goldberg, D. E., Identification 
and characterization of falcilysin, a metallopeptidase involved in 
hemoglobin catabolism within the malarial parasite Plasmodium 
falciparum. J. Biol. Chem., 1999, 274, 32411–32417. 
89. Rosenthal, P. J., Hydrolysis of erythrocyte proteins by proteases 
of malarial parasites. Curr. Opin. Hematol., 2002, 9, 140–145. 
90. Deprez-Poulani, R. and Melnyk, P., 1,4-Bis(3-aminopropyl) 
piperazine libraries: From the discovery of classical chloroquine-
like antimalarials to the identification of new targets. Combinato-
rial Chem.
 
High Throughput Screening, 2005, 8, 39–48.  
91. Chen, X., Chong, C. R., Shi, L., Yoshimoto, T., Sullivan Jr., D. 
and Liu, J. O., Inhibitor of Plasmodium falciparum amino- 
peptidase 1b possess antimalarial activity. Proc. Natl. Acad. Sci. 
USA, 2006, 103, 14548–14553. 
92. Vial, H. and Ancelin, M., Malarial lipids. In Malaria: Parasite 
Biology, Biogenesis, Protection, ASM Press, Washington DC, 
1998, pp. 159–175. 
93. Calas, M., Ancelin, M. L., Cordma, G., Portefaix, P., Piquet, G., 
Vidal-Sailhan, V. and Vial, H., Antimalarial activity of com-
pounds interfering with Plasmodium falciparum phospholipid me-
tabolism: comparison between mono- and bis-quaternary ammonium 
salts. J. Med. Chem., 2000, 43, 505–516. 
94. Salom-Roid, X. J., Hamze, A., Calas, M. and Vial, H. J., Dual 
molecules as new antimalarials. Combinatorial Chem. High 
Throughput Screening, 2005, 8, 49–62. 
95. Staines, H. M., Ellory, J. C. and Chibale, K., The new permeabil-
ity pathways: Targets and selective routes for the development of 
new antimalarial agents. Combinatorial Chem. High Throughput 
Screening, 2005, 8, 81–88. 
96. Kirk, K., Membrane transport in the malaria-infected erythrocyte. 
Physiol. Rev., 2001, 81, 495–537. 
97. Staines, H. M. et al., Furosemide analogues as potent inhibitors of 
the new permeability pathways of Plasmodium falciparum-
infected human erythrocytes. Mol. Biochem. Parasitol., 2004, 
133, 315–318. 
98. Lauer, S. A., Rathod, P. K., Ghori, N. and Haldar, K., A mem-
brane network for nutrient import in red cells infected with ma-
laria parasite. Science, 1997, 276, 1122–1125. 
99. Ang, K. K. H., Holmes, M. J., Higa, J., Hamann, M. T. and Kara, 
U. A. K., In vivo antimalarial activity of the beta-carboline alka-
loid Menzamine A. Antimicrob. Agents Chemother., 2000, 44, 
1645–1649.  
100. Raju, R. C., Vathsala, P. G., Keshamouni, V. G., Padmanaban, G. 
and Rangarajan, P. N., Curcumin for malaria therapy. Biochem. 
Biophys. Res. Commun., 2005, 326, 472–474. 
101. Nandakumar, D. N., Nagaraj, V. A., Vathsala, P. G., Rangarajan, 
P. N. and Padmanaban, G., Curcumin–artemisinin combination therapy 
for malaria. Antimicrob. Agents Chemother., 2006, 50, 1859–1860. 
102. Carraz, M. et al., A plant-derived morphinan as a novel lead com-
pound active against malaria liver stages. PLOS Med. 2006, 3, e513. 
103. Wicox, M., Bodekar, G. and Raspanaivo, P., Traditional Medici-
nal Plants and Malaria, CRC Press, Boca Raton, 2004. 
104. Vennerstrom, J. L. et al., Identification of an antimalarial syn-
thetic trioxalane drug development candidate. Nature, 2004, 430, 
900–904. 
105. Posner, G. H. et al., Malaria-infected mice are cured by a single 
dose of novel artemisinin derivatives. J. Med. Chem., 2007, DOI 
10. 1021/jm 07014m. 
 
ACKNOWLEDGEMENTS. Studies carried out in the authors’ labo-
ratory were supported by the Department of Biotechnology and De-
partment of Science and Technology, New Delhi. 
 
 
 
 
 
 
  
 
 
